Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Active, not recruiting, industry sponsors, Infectious disease and vaccines, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed502
7 trials
Showing 1 to 7, recently updated first.
- Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Active, not recruiting
SanofiSanofi (SNY)
NCT07861542 · 669 participants · Start Oct 1, 2026 · Primary completion Nov 26, 2026
Drug: Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M · For: COVID-19
Sites: Fair Oaks, California; Doral, Florida; Atlanta, Georgia · 20 sites in all
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Pivotal-lookingActive, not recruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07266558 · 30,000 participants · Start Nov 26, 2025 · Primary completion Jun 16, 2027
Drug: mRNA-1273; mRNA-1283 and 1 more · For: SARS-CoV-2
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 150 sites in all
- A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06113198 · 50 participants · Start Nov 10, 2023 · Primary completion Sep 7, 2026
Drug: rMenB+OMV NZ · For: Meningitis, Meningococcal
Sites: Incheon, South Korea; Junggu, South Korea; Kyungki-do, South Korea · 8 sites in all
- Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in IndiaActive, not recruiting
SanofiSanofi (SNY)
NCT07109297 · 110 participants · Start Jul 31, 2025 · Primary completion Jun 30, 2026
Drug: Nirsevimab · For: RSV Immunization
Sites: Bengaluru, India; Jaipur, India; Kolkata, India · 7 sites in all
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)Pivotal-lookingActive, not recruiting
CanSino Biologics Inc.Industry
NCT05935176 · 660 participants · Start Sep 20, 2023 · Primary completion May 15, 2026
Drug: MCV4; MCV4 and 1 more · For: Epidemic Meningitis
Sites: Jiaozuo, China
- Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHBActive, not recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06743438 · 640 participants · Start Mar 10, 2022 · Primary completion Jun 30, 2024
Drug: Tenofovir Amibufenamide(TMF) · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- Clinical Trial of MicaPivotal-lookingActive, not recruiting
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
NCT05680415 · 6,800 participants (planned) · Start Apr 19, 2023 · Primary completion Sep 30, 2026
Drug: Mycobacterium Vaccae for Injection · For: Latent Tuberculosis Infection
Sites: Liuzhou, China · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.